Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

56.90
+0.81001.44%
Post-market: 57.000.1000+0.18%19:58 EDT
Volume:2.36M
Turnover:133.23M
Market Cap:8.71B
PE:20.55
High:57.87
Open:56.18
Low:54.70
Close:56.09
52wk High:59.30
52wk Low:26.76
Shares:153.09M
Float Shares:141.54M
Volume Ratio:1.47
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):2.77
ROE:100.28%
ROA:7.28%
PB:14.42
PE(LYR):20.54

Loading ...

Goldman Sachs Reaffirms Their Hold Rating on TG Therapeutics (TGTX)

TIPRANKS
·
Apr 16

TG Therapeutics completes enrollment in Phase 3 subcutaneous Briumvi trial in MS

Reuters
·
Apr 15

TG Therapeutics Inc - Top-Line Data From Phase 3 Subcutaneous Briumvi Trial Expected Year-End 2026 or Q1 2027

THOMSON REUTERS
·
Apr 15

Analysts Conflicted on These Healthcare Names: TG Therapeutics (TGTX), Insmed (INSM) and Solventum Corporation (SOLV)

TIPRANKS
·
Apr 08

TG Therapeutics Credit Deal And Valuation Gap Catch Investor Attention

Simply Wall St.
·
Mar 22

TG Therapeutics Files Procedural 8-K on Financial Obligation

TIPRANKS
·
Mar 21

TG Therapeutics enters USD 750 billion term loan amendment with Blue Owl Capital Corporation-led lenders

Reuters
·
Mar 21

BRIEF-TG Therapeutics Secures An Additional $500 Million In Non-Dilutive Capital From Blue Owl And Expands Share Repurchase Program To $300 Million

Reuters
·
Mar 19

TG Therapeutics Inc - Enters Five-Year $750 Mln Credit Facility With Blue Owl Capital

THOMSON REUTERS
·
Mar 19

TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital From Blue Owl and Expands Share Repurchase Program to $300 Million

THOMSON REUTERS
·
Mar 19

TG Therapeutics Inc - Increases Share Repurchase Program to $300 Mln

THOMSON REUTERS
·
Mar 19

TG Therapeutics announces publication of data from studies on Briumvi

TIPRANKS
·
Mar 09

Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

GlobeNewswire
·
Mar 09